RecruitingPhase 4NCT05029050

Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart Surgery

Alpha 2 Adrenergic Receptor Agonists for the Prevention of Delirium and Cognitive Decline After Open Heart Surgery (ALPHA2PREVENT): Randomised Controlled Trial.


Sponsor

Oslo University Hospital

Enrollment

900 participants

Start Date

Jan 17, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.


Eligibility

Min Age: 70 Years

Inclusion Criteria4

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Participant must be ≥70 years old at the time of signing the informed consent.
  • Participant must be accepted for cardiac surgery with cardiopulmonary bypass. The surgical procedures may constitute 1) coronary bypass grafting, 2) tricuspid, mitral, or aortic valve replacement or repair, 3) surgery on the ascending aorta, and 4) the combination any of these procedures.
  • Participant must be capable of giving signed informed consent.

Exclusion Criteria19

  • Participants are excluded from the study if any of the following criteria apply:
  • Preoperative delirium
  • Known hypersensitivity to the active ingredient or components of the product
  • Bradycardia due to sick-sinus-syndrome, 2nd or 3rd degree AV-block (if not treated with pacemaker) or any other reason causing HR <50 bpm at time of inclusion
  • Uncontrolled hypotension
  • Ischemic stroke or transitory ischemic attack the last month or critical peripheral ischemia
  • Acute coronary syndrome last 24 hours. Acute coronary syndrome is defined according to international guidelines
  • Left ventricular ejection fraction < 40%
  • Severe renal impairment (estimated GFR <20ml/min) or expected requirement for renal replacement therapy
  • Severe hepatic dysfunction (liver enzyme three times the upper limit of normal together with a serum albumin concentration below the normal reference limit)
  • Reduced peripheral autonomous activity (e.g. spinal cord injury)
  • Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin
  • Endocarditis or sepsis
  • Pheochromocytoma
  • Planned deep hypothermia and circulatory arrest
  • Emergency surgery, defined as less than 24 hours from admission to surgery
  • Previously included in this study
  • Not speaking or reading Norwegian
  • Any other condition as evaluated by the treating physician

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexmedetomidine

Continous intravenous infusion

DRUGClonidine

Continous intravenous infusion

DRUGNatriumchlorid

Continous intravenous infusion NaCl


Locations(5)

Haukeland University Hospital

Bergen, Norway

Oslo University Hospital Rikshospitalet

Oslo, Norway

Oslo University Hospital Ullevål

Oslo, Norway

University Hospital of North Norway

Tromsø, Norway

St Olav University Hospital

Trondheim, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05029050


Related Trials